Genetic
BPX-601
BPX-601 is a genetic therapy with 2 clinical trials. Currently 1 active trials ongoing.
Total Trials
2
Max Phase
—
Type
GENETIC
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
1(50%)
Terminated
1(50%)
Phase Distribution
Ph phase_1
2
100%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(1)
Terminated(1)
Detailed Status
Terminated1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
0.0%
Most Advanced
Phase 1
Trials by Phase
Phase 12 (100.0%)
Trials by Status
terminated150%
recruiting150%
Recent Activity
1 active trials
Showing 2 of 2
recruitingphase_1
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
NCT07543055
terminatedphase_1
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
NCT02744287
Clinical Trials (2)
Showing 2 of 2 trials
NCT07543055Phase 1
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
NCT02744287Phase 1
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
All 2 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 2